Research ExplorerPublicationsMicrovesicle-associated tissue factor procoagulant activity ...

Microvesicle-associated tissue factor procoagulant activity for the preoperative diagnosis of ovarian cancer

Standard

Microvesicle-associated tissue factor procoagulant activity for the preoperative diagnosis of ovarian cancer. / Claussen, Carlota; Rausch, Alma-Verena; Lezius, Susanne; Amirkhosravi, Ali; Davila, Monica; Francis, John L; Hisada, Yohei M; Mackman, Nigel; Bokemeyer, Carsten; Schmalfeldt, Barbara; Mahner, Sven; Langer, Florian.

In: THROMB RES, Vol. 141, 02.03.2016, p. 39-48.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Claussen, C, Rausch, A-V, Lezius, S, Amirkhosravi, A, Davila, M, Francis, JL, Hisada, YM, Mackman, N, Bokemeyer, C, Schmalfeldt, B, Mahner, S & Langer, F 2016, 'Microvesicle-associated tissue factor procoagulant activity for the preoperative diagnosis of ovarian cancer', THROMB RES, vol. 141, pp. 39-48. https://doi.org/10.1016/j.thromres.2016.03.002

APA

Claussen, C., Rausch, A-V., Lezius, S., Amirkhosravi, A., Davila, M., Francis, J. L., Hisada, Y. M., Mackman, N., Bokemeyer, C., Schmalfeldt, B., Mahner, S., & Langer, F. (2016). Microvesicle-associated tissue factor procoagulant activity for the preoperative diagnosis of ovarian cancer. THROMB RES, 141, 39-48. https://doi.org/10.1016/j.thromres.2016.03.002

Vancouver

Claussen C, Rausch A-V, Lezius S, Amirkhosravi A, Davila M, Francis JL et al. Microvesicle-associated tissue factor procoagulant activity for the preoperative diagnosis of ovarian cancer. THROMB RES. 2016 Mar 2;141:39-48. https://doi.org/10.1016/j.thromres.2016.03.002

Bibtex

@article{4254aa47fc8843fdb70974ab0f90851c,
title = "Microvesicle-associated tissue factor procoagulant activity for the preoperative diagnosis of ovarian cancer",
abstract = "BACKGROUND: Tissue factor (TF) is involved in tumor growth and metastasis and contributes to venous thromboembolism (VTE) in cancer, including gynecological malignancies. The diagnostic value of microvesicle-associated TF procoagulant activity (MV TF PCA) in women with suspected ovarian cancer, however, has not been studied.OBJECTIVE: To evaluate MV TF PCA as a diagnostic tool in women with an ovarian mass of unknown etiology and as a predictive biomarker for perioperative VTE.METHODS: Plasma MVs were isolated by high-speed centrifugation and analyzed for TF-specific PCA by single-stage clotting assay. In addition, plasma TF antigen and soluble P-selectin (sCD62P) were measured by ELISA.RESULTS: D-Dimer, MV TF PCA, and sCD62P, but not the tumor marker, CA-125, significantly differentiated patients with malignant (n=40) from those with benign tumors (n=15) and healthy controls (n=34). In cancer patients, only D-Dimer and CA-125 correlated with the FIGO stage. An abnormal D-dimer had the highest sensitivity for the diagnosis of cancer, while MV TF PCA above the ROC curve-derived cut-off value of 182U/mL had the highest specificity. By multivariate logistic regression analysis, addition of MV TF PCA conferred diagnostic benefit to the single variables, CA-125 (p=0.052) and D-dimer (p=0.019). Perioperative VTE occurred in 16% of cancer patients and was associated with an advanced FIGO stage, but not MV TF PCA. There was no difference in plasma TF antigen levels between study groups.CONCLUSIONS: MV TF PCA, but not plasma TF antigen, may provide valuable additional information for the diagnostic work-up of women with suspected ovarian cancer.",
author = "Carlota Claussen and Alma-Verena Rausch and Susanne Lezius and Ali Amirkhosravi and Monica Davila and Francis, {John L} and Hisada, {Yohei M} and Nigel Mackman and Carsten Bokemeyer and Barbara Schmalfeldt and Sven Mahner and Florian Langer",
note = "Copyright {\textcopyright} 2016 Elsevier Ltd. All rights reserved.",
year = "2016",
month = mar,
day = "2",
doi = "10.1016/j.thromres.2016.03.002",
language = "English",
volume = "141",
pages = "39--48",
journal = "THROMB RES",
issn = "0049-3848",
publisher = "Elsevier Limited",

}

RIS

TY - JOUR

T1 - Microvesicle-associated tissue factor procoagulant activity for the preoperative diagnosis of ovarian cancer

AU - Claussen, Carlota

AU - Rausch, Alma-Verena

AU - Lezius, Susanne

AU - Amirkhosravi, Ali

AU - Davila, Monica

AU - Francis, John L

AU - Hisada, Yohei M

AU - Mackman, Nigel

AU - Bokemeyer, Carsten

AU - Schmalfeldt, Barbara

AU - Mahner, Sven

AU - Langer, Florian

N1 - Copyright © 2016 Elsevier Ltd. All rights reserved.

PY - 2016/3/2

Y1 - 2016/3/2

N2 - BACKGROUND: Tissue factor (TF) is involved in tumor growth and metastasis and contributes to venous thromboembolism (VTE) in cancer, including gynecological malignancies. The diagnostic value of microvesicle-associated TF procoagulant activity (MV TF PCA) in women with suspected ovarian cancer, however, has not been studied.OBJECTIVE: To evaluate MV TF PCA as a diagnostic tool in women with an ovarian mass of unknown etiology and as a predictive biomarker for perioperative VTE.METHODS: Plasma MVs were isolated by high-speed centrifugation and analyzed for TF-specific PCA by single-stage clotting assay. In addition, plasma TF antigen and soluble P-selectin (sCD62P) were measured by ELISA.RESULTS: D-Dimer, MV TF PCA, and sCD62P, but not the tumor marker, CA-125, significantly differentiated patients with malignant (n=40) from those with benign tumors (n=15) and healthy controls (n=34). In cancer patients, only D-Dimer and CA-125 correlated with the FIGO stage. An abnormal D-dimer had the highest sensitivity for the diagnosis of cancer, while MV TF PCA above the ROC curve-derived cut-off value of 182U/mL had the highest specificity. By multivariate logistic regression analysis, addition of MV TF PCA conferred diagnostic benefit to the single variables, CA-125 (p=0.052) and D-dimer (p=0.019). Perioperative VTE occurred in 16% of cancer patients and was associated with an advanced FIGO stage, but not MV TF PCA. There was no difference in plasma TF antigen levels between study groups.CONCLUSIONS: MV TF PCA, but not plasma TF antigen, may provide valuable additional information for the diagnostic work-up of women with suspected ovarian cancer.

AB - BACKGROUND: Tissue factor (TF) is involved in tumor growth and metastasis and contributes to venous thromboembolism (VTE) in cancer, including gynecological malignancies. The diagnostic value of microvesicle-associated TF procoagulant activity (MV TF PCA) in women with suspected ovarian cancer, however, has not been studied.OBJECTIVE: To evaluate MV TF PCA as a diagnostic tool in women with an ovarian mass of unknown etiology and as a predictive biomarker for perioperative VTE.METHODS: Plasma MVs were isolated by high-speed centrifugation and analyzed for TF-specific PCA by single-stage clotting assay. In addition, plasma TF antigen and soluble P-selectin (sCD62P) were measured by ELISA.RESULTS: D-Dimer, MV TF PCA, and sCD62P, but not the tumor marker, CA-125, significantly differentiated patients with malignant (n=40) from those with benign tumors (n=15) and healthy controls (n=34). In cancer patients, only D-Dimer and CA-125 correlated with the FIGO stage. An abnormal D-dimer had the highest sensitivity for the diagnosis of cancer, while MV TF PCA above the ROC curve-derived cut-off value of 182U/mL had the highest specificity. By multivariate logistic regression analysis, addition of MV TF PCA conferred diagnostic benefit to the single variables, CA-125 (p=0.052) and D-dimer (p=0.019). Perioperative VTE occurred in 16% of cancer patients and was associated with an advanced FIGO stage, but not MV TF PCA. There was no difference in plasma TF antigen levels between study groups.CONCLUSIONS: MV TF PCA, but not plasma TF antigen, may provide valuable additional information for the diagnostic work-up of women with suspected ovarian cancer.

U2 - 10.1016/j.thromres.2016.03.002

DO - 10.1016/j.thromres.2016.03.002

M3 - SCORING: Journal article

C2 - 26967531

VL - 141

SP - 39

EP - 48

JO - THROMB RES

JF - THROMB RES

SN - 0049-3848

ER -